Tamia Nguyen

1.1k total citations · 1 hit paper
15 papers, 465 citations indexed

About

Tamia Nguyen is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Tamia Nguyen has authored 15 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 8 papers in Hematology and 3 papers in Molecular Biology. Recurrent topics in Tamia Nguyen's work include Chronic Lymphocytic Leukemia Research (9 papers), Acute Myeloid Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Tamia Nguyen is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Acute Myeloid Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Tamia Nguyen collaborates with scholars based in Australia, Austria and Germany. Tamia Nguyen's co-authors include Piers Blombery, David Westerman, Andrew W. Roberts, John F. Seymour, Constantine S. Tam, Mary Ann Anderson, Thomas E. Lew, Ella R. Thompson, David C.S. Huang and Rachel Thijssen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Tamia Nguyen

14 papers receiving 462 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Tamia Nguyen

Since Specialization

Citations

This map shows the geographic impact of Tamia Nguyen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamia Nguyen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamia Nguyen more than expected).

Fields of papers citing papers by Tamia Nguyen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamia Nguyen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamia Nguyen. The network helps show where Tamia Nguyen may publish in the future.

Co-authorship network of co-authors of Tamia Nguyen

This figure shows the co-authorship network connecting the top 25 collaborators of Tamia Nguyen. A scholar is included among the top collaborators of Tamia Nguyen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamia Nguyen. Tamia Nguyen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer 2025 ·Blood Advances ·Ing Soo Tiong, Tamia Nguyen, Chong Chyn Chua, Charis E. Teh, (unknown), Sarah Ftouni, John F. Seymour, Daniel H.D. Gray, Andrew W. Roberts, Sarah‐Jane Dawson, Geoffrey J. Lindeman, Piers Blombery	0
2	Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) 2024 ·Journal of Clinical Oncology ·Ing Soo Tiong, Devendra Hiwase, (unknown), Ashish Bajel, (unknown), (unknown), John Reynolds, Natasha S. Anstee, Tamia Nguyen, Sun Loo, Chong Chyn Chua, Michael Ashby, (unknown), Shaun Fleming, Chun Yew Fong, (unknown), Piers Blombery, Richard Dillon, Adam Ivey, Andrew H. Wei	18
3	Evaluation of T‐cell clonality by anti‐TRBC1 antibody‐based flow cytometry and correlation with T‐cell receptor sequencing 2023 ·British Journal of Haematology ·Phillip Nguyen, Tamia Nguyen, (unknown), Ing Soo Tiong, (unknown), Vuong Nguyen, Neil Came, Piers Blombery, David Westerman	2
4	Persistence of UBTF tandem duplications in remission in acute myeloid leukaemia 2023 ·SHILAP Revista de lepidopterología ·(unknown), Phillip Nguyen, David J. Byrne, (unknown), Georgina L. Ryland, Tamia Nguyen, Mary Ann Anderson, Seong Lin Khaw, (unknown), Ing Soo Tiong, Elaine Sanij, Piers Blombery	3
5	BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms 2023 ·Blood ·Ing Soo Tiong, Tamia Nguyen, Charis E. Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E. Lew, Fiona C. Brown, Donia M. Moujalled, (unknown), Daniel H.D. Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah‐Jane Dawson, Andrew H. Wei, Geoffrey J. Lindeman, Piers Blombery	3
6	Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy 2022 ·Blood ·Anna Maierhofer, Lucy C. Fox, Stephan Hütter, Constance Baer, Ella R. Thompson, Tamia Nguyen, Nicole den Elzen, Robin Filshie, Ing Soo Tiong, Niroshan Nadarajah, Manja Meggendorfer, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, Piers Blombery	1
7	Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors 2021 ·Blood Advances ·Ella R. Thompson, Tamia Nguyen, (unknown), John Markham, Mary Ann Anderson, Sasanka M. Handunnetti, Rachel Thijssen, Paul Yeh, Constantine S. Tam, John F. Seymour, Andrew W. Roberts, David Westerman, Piers Blombery	17
8	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL 2021 ·Blood ·Piers Blombery, Thomas E. Lew, Michael A. Dengler, Ella R. Thompson, Victor S. Lin, Xiangting Chen, Tamia Nguyen, Ashis Kumar Panigrahi, Sasanka M. Handunnetti, Dennis Carney, David Westerman, Constantine S. Tam, Jerry M. Adams, Andrew H. Wei, David C.S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson	47
9	Clonal independence of <i>JAK2</i> and <i>CALR</i> or <i>MPL</i> mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing 2020 ·Haematologica ·Ella R. Thompson, Tamia Nguyen, (unknown), Paul Yeh, (unknown), Michelle McBean, Timothy Semple, Gisela Mir Arnau, Kate Burbury, Nora Lee, Amit Khot, David Westerman, Piers Blombery	14
10	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax 2020 ·Blood ·Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti, Piers Blombery, Tamia Nguyen, David Westerman, Bryone J. Kuss, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Mary Ann Anderson	61
11	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia 2020 ·Blood ·Piers Blombery, Ella R. Thompson, Xiangting Chen, Tamia Nguyen, Mary Ann Anderson, David Westerman, John F. Seymour, Constantine S. Tam, Michael A. Dengler, David C.S. Huang, Andrew H. Wei, Andrew W. Roberts	6
12	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia 2020 ·Blood ·Ella R. Thompson, Tamia Nguyen, (unknown), Mary Ann Anderson, Sasanka M. Handunnetti, Rachel Thijssen, Paul Yeh, Constantine S. Tam, John F. Seymour, Andrew W. Roberts, David Westerman, Piers Blombery	5
13	Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax 2019 ·Blood ·Piers Blombery, Ella R. Thompson, Tamia Nguyen, Xiangting Chen, Michelle McBean, Richard W. Birkinshaw, Peter E. Czabotar, Rachel Thijssen, Mary Ann Anderson, John F. Seymour, David Westerman, David C.S. Huang, Andrew W. Roberts	3
14	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia breakdown → 2018 ·Cancer Discovery ·Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts	276
15	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia 2018 ·Blood ·Piers Blombery, Mary Ann Anderson, Jianan Gong, Rachel Thijssen, Richard W. Birkinshaw, Ella R. Thompson, Charis E. Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E. Lew, Ian J. Majewski, Daniel H.D. Gray, David Westerman, Constantine S. Tam, John F. Seymour, Peter E. Czabotar, David C.S. Huang, Andrew W. Roberts	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact